- UNC-TV Series
- UNC-TV Specials
- Programs A-Z
- UNC-TV Science
Dr. Stuart Gold, M.D.
Professor, Pediatric Hematology/Oncology, UNC-Chapel Hill
Outpatient Clinic Director, Pediatric Oncology Division
Dr. Gold is an accomplished clinical research specialist with special interests in acute leukemia's brain tumors and late effects of cancer therapy and heads a comprehensive brain tumor clinic, which brings together experts from the disciplines of neurology, neurosurgery, radiology, psychology and sociology. Dr. Gold also runs monthly clinics in Wilmington and Raleigh that serve the pediatric oncology needs of those communities. In addition, he serves on multiple important cancer committees, including several with the Children's Cancer Group (CCG), the largest group of pediatric cancer institutions in the world, pooling its resources and patients to advance the treatment outcomes for children with cancer. Dr. Gold has completed a study of long-term survivors of childhood cancer. In collaboration with investigators at Duke University, he is the principle investigator of a phase I trial of an ara-G analogue for recurrent leukemia and lymphoma.
Joanne Kurtzberg, M.D.
Professor of Pediatrics
Founder and Director, Duke Pediatric Bone Marrow and Stem Cell Transplant Program
Director of the Carolina Cord Blood Bank
Dr. Kurtzberg is a pioneering researcher in cord blood transplantation and an internationally recognized leader in stem cell research and transplantation in children. The Duke Pediatric Bone Marrow and Stem Cell Transplant Program is the largest children's transplant program in the world , dedicated to providing outstanding care and support to pediatric patients who can be helped by transplantation therapy. Using a variety of approaches, the program has pioneered the use of both matched and mismatched umbilical cord blood stem cells in patients who do not have a sibling donor. Under the direction of Dr. Kurtzberg, the program has performed approximately 1200 autologous and allogeneic transplants in children with cancer or genetic diseases since 1990. Today, over half of these children are surviving long-term, cured of their underlying disease by their transplant.
Sharon Castellino, M.D.
Wake Forest University Baptist Medical Center
Brenner Children's Hospital
Board Certified Pediatric, Hematology/Oncology
Clinical Interests: Late effect in Pediatric Oncology,
Thrombophilia, Pediatric Leukeumias
Research Interests: Late effects after childhood cancer treatment
Director of Research and Advocacy for the Pediatric Brain Tumor Foundation
The Pediatric Brain Tumor Foundation (PBTF) is a national organization dedicated to supporting the search for the cause and cure of childhood brain tumors. This mission grew from the desire of the co-founders, Mike and Dianne Traynor, to bring an end to the untimely death of children from this disease. The Traynors were introduced to this devastating disease through the struggle and pain of a colleague whose child was stricken with a brain tumor. They also created Ride for Kids®, and it continues to function as a grassroots effort by the motorcycling community of the United States to bring about a change in a devastating diagnosis for thousands of children. Today the Ride for Kids is the primary source of funding for the Pediatric Brain Tumor Foundation. As a result of the success and growth of the Ride for Kids program, the Traynors founded the Pediatric Brain Tumor Foundation in 1991.
Sri Gururangan MRCP (UK)
Director of Pediatric Clinical Services
Associate Professor of Pediatrics
Associate Professor of Surgery
Dr. Gururangan is a pediatric neuro-oncologist responsible for designing and providing care to children with brain and spinal cord tumors. Dr. "Sri" Gururangan focuses exclusively on the clinical care of children with brain tumors. Over the last 10 years, he has had extensive experience in the treatment of children with cancers, particularly brain tumors, in several premier institutions in the United States, England, Ireland, and most recently at Memorial Sloan-Kettering Cancer Center in New York. He designs clinical protocols, which utilize the newest advances in the treatment of children with these tumors.